American Century Companies Inc. Sells 30,180 Shares of Zoetis Inc. $ZTS

American Century Companies Inc. reduced its position in Zoetis Inc. (NYSE:ZTS) by 2.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,392,314 shares of the company’s stock after selling 30,180 shares during the quarter. American Century Companies Inc. owned approximately 0.32% of Zoetis worth $203,723,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. Halbert Hargrove Global Advisors LLC increased its holdings in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares during the last quarter. NewSquare Capital LLC lifted its holdings in Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. Financial Consulate Inc. bought a new position in Zoetis during the third quarter worth about $39,000. SJS Investment Consulting Inc. increased its stake in shares of Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after purchasing an additional 257 shares in the last quarter. Finally, TruNorth Capital Management LLC purchased a new position in shares of Zoetis in the third quarter worth about $42,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $131.06 on Friday. The stock has a market cap of $55.32 billion, a P/E ratio of 21.77, a PEG ratio of 2.00 and a beta of 0.96. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The business’s 50-day moving average price is $126.05 and its two-hundred day moving average price is $134.05. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $177.00.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.6%. Zoetis’s dividend payout ratio is presently 35.22%.

Analyst Ratings Changes

ZTS has been the topic of a number of recent research reports. Bank of America upped their price target on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. HSBC set a $140.00 price target on Zoetis in a report on Wednesday, December 10th. Morgan Stanley set a $160.00 price objective on Zoetis in a research note on Thursday, December 18th. The Goldman Sachs Group raised Zoetis to a “buy” rating in a report on Monday, December 15th. Finally, Stifel Nicolaus reduced their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a report on Tuesday, November 18th. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.